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Abstract
Increased polyamine concentrations in the blood and urine of cancer patients reflect the enhanced levels of
polyamine synthesis in cancer tissues arising from increased activity of enzymes responsible for polyamine
synthesis. In addition to their de novo polyamine synthesis, cells can take up polyamines from extracellular sources,
such as cancer tissues, food, and intestinal microbiota. Because polyamines are indispensable for cell growth,
increased polyamine availability enhances cell growth. However, the malignant potential of cancer is determined
by its capability to invade to surrounding tissues and metastasize to distant organs. The mechanisms by which
increased polyamine levels enhance the malignant potential of cancer cells and decrease anti-tumor immunity are
reviewed. Cancer cells with a greater capability to synthesize polyamines are associated with increased production
of proteinases, such as serine proteinase, matrix metalloproteinases, cathepsins, and plasminogen activator, which
can degrade surrounding tissues. Although cancer tissues produce vascular growth factors, their deregulated
growth induces hypoxia, which in turn enhances polyamine uptake by cancer cells to further augment cell
migration and suppress CD44 expression. Increased polyamine uptake by immune cells also results in reduced
cytokine production needed for anti-tumor activities and decreases expression of adhesion molecules involved in
anti-tumor immunity, such as CD11a and CD56. Immune cells in an environment with increased polyamine levels
lose anti-tumor immune functions, such as lymphokine activated killer activities. Recent investigations revealed that
increased polyamine availability enhances the capability of cancer cells to invade and metastasize to new tissues
while diminishing immune cells’ anti-tumor immune functions.
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1. Introduction
Polyamines, which include spermidine and spermine, are
polycations with three or four amine groups. Almost all
cells can produce polyamines, but their production is
especially high in rapidly growing cells. Polyamine con-
centrations are often increased in the blood and urine of
cancer patients, and these increased levels have been
shown to correlate with poor prognosis [1]. The
increased blood and urinary polyamine levels are attri-
butable to increased polyamine synthesis by cancer cells,
since these increases can be abolished by complete era-
dication of tumors by surgery or radio-chemotherapy
[2-5]. The capacity of cancer tissue to produce abundant
polyamines likely contributes to cancer cells’ enhanced
growth rates because polyamines are indispensable for
cellular growth, which may at least partially explain why
cancer patients with increased polyamine levels have a
poorer prognosis [4-9]. However, an important factor
that determines the malignant potential of cancer cells
is the capability of cells to invade to surrounding tissues
and to metastasize to distant organs. Therefore, it is
important to understand the role of polyamines in can-
cer invasion and metastasis. In this review, recent
experimental results from our and other groups are
discussed.
2. What are polyamines?
The natural polyamines, spermidine, and spermine, are
found in almost every living cell at high micromolar to
low millimolar quantities [10]. Polyamines are synthe-
sized from arginine and s-adenosylmethionine with argi-
nase converting arginine to ornithine, and ornithine
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tion to form putrescine, a polyamine precursor contain-
ing two amine groups (Figure 1). Polyamines are
involved in diverse functions involved in cell growth and
differentiation, such as DNA synthesis and stability, reg-
ulation of transcription, ion channel regulation, and pro-
tein phosphorylation [11-14].
Intracellular spermine and spermidine are degraded by
spermidine/spermine N
1-acetyltransferase (SSAT) and
N
1-acetylpolyamine oxidase (APAO). SSAT, a highly
inducible enzyme, catalyzes the transfer of an acetyl
group from acetyl-coenzyme A to the aminopropyl moi-
ety of spermine and spermidine. APAO was previously
described as polyamine oxidase but it preferentially cata-
lyzes the oxidation of the N
1-acetylspermine and N
1-
acetylspermidine produced by SSAT activity. This
oxidation results in the production of H2O2, 3-acetoami-
nopropanal, and putrescine or spermidine (Spd),
depending on the initial substrate [15-17]. Mammalian
spermine oxidase (SMO) is an inducible enzyme that
specifically oxidizes spermine, with the production of
H2O2, 3-aminopropanal (3AP) and spermidine [16,17].
In addition to de novo synthesis and degradation, cel-
lular polyamine concentrations are also regulated by
transmembrane transport where cells take up polya-
mines from their surroundings or export them to the
extracellular space (Figure 1).
3. Polyamines and cancer
Polyamine biosynthesis is up-regulated in actively grow-
ing cells, including cancer cells [10,18,19], therefore
polyamine concentration as well as gene expression and
activity of enzymes involved in polyamine biosynthesis,
especially ODC, are higher in cancer tissues than in nor-
mal surrounding tissues [8,20-25].
Numerous reports have shown that both blood and
urine polyamine concentrations are often increased in
cancer patients [4,5,7,8,10]. A close correlation between
blood polyamine levels and the amount of urinary polya-
mines has also been found in cancer patients [1]. More-
over, these levels decrease after tumor eradication and
increase after relapse [2-5,23], indicating that polya-
mines synthesized by cancer tissues are transferred to
the blood circulation and kidney, where they are
excreted into the urine [26].
Polyamines are also produced in other parts of the
body and can be transported to various organs and tis-
sues such as the intestinal lumen where polyamines are
absorbed quickly to increase portal vein polyamine con-
centrations [27]. The majority of spermine and spermi-
dine in the intestinal lumen is absorbed in their original
forms because there is no apparent enzymatic activity
present to catalyze their degradation [28]. Polyamines
absorbed by the intestinal lumen are distributed to
almost all organs and tissues in the body [29] as demon-
strated by the increased blood polyamine levels in ani-
mals and humans produced in response to continuous
enhanced polyamine intake for six and two months,
respectively [30,31]. However, short-term increased
polyamine intake failed to produce such increases
[30-32], possibly because of the homeostasis that inhi-
bits acute changes in intracellular polyamine concentra-
tion. On the other hand, reductions in blood polyamine
concentration were not achieved only by restricting oral
polyamine intake. As such, at least two sources of intest-
inal polyamines are postulated: foods and intestinal
microbiota. Decrease in blood polyamine levels can be
successfully achieved by eliminating intestinal micro-
biota in addition to restricting food polyamines [33].
Taken together, these results indicate that polyamines
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Figure 1 Polyamine biosynthesis, degradation, and
transmembrane transport. The polyamines spermine and
spermidine are synthesized from arginine. Arginase converts
arginine to ornithine, and ornithine decarboxylase (ODC) catalyzes
decarboxylation of ornithine to form putrescine, a polyamine
precursor containing two amine groups. ODC, a rate-limiting
enzyme with a short half-life, is inhibited by antizyme, and antizyme
is inhibited by an antizyme inhibitor. S-adenosylmethionine
decarboxylase (AdoMetDC) is the second rate-limiting enzyme in
polyamine synthesis and is involved in the decarboxylation of S-
adenosylmethionine. Spermidine synthetase and spermine synthase
are constitutively expressed aminopropyltransferases that catalyze
the transfer of the aminopropyl group from decarboxylated S-
adenosylmethionine to putrescine and spermidine to form
spermidine and spermine, respectively. Polyamine degradation is
achieved by spermine/spermidine N
1-acetyltransferase (SSAT) and
N
1-acetylpolyamine oxidase (APAO). In addition, spermine oxidase
(SMO) specifically oxidizes spermine. Polyamines are transported
across the membrane transmembrane by the polyamine transporter.
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supplied from the intestinal lumen and together appear
to influence polyamine levels in the body of cancer
patients.
3. Polyamines in the body
In vitro experiments showed that cultured cells take up
polyamines from their surroundings [34,35]. In blood
circulation, the majority of polyamines are contained in
blood cells, especially in red and white blood cells, and
therefore increases in blood polyamine concentration
indicate concurrent increases in polyamine levels in
blood cells [36]. Similarly, intracellular polyamine con-
centrations in cells of otherwise normal tissues and
organs in cancer patients can be increased [37]. One
examination showed that spermidine and spermine
levels are increased in the normal colon mucosa of can-
cer patients compared to the normal colon mucosa
from patients without cancer [37], although another
study was unable to detect these differences [38]. Given
that polyamine concentrations are increased in the
blood cells of cancer patients and numerous blood cells
with increased polyamine concentrations exist in normal
tissues, the polyamine concentration in normal tissues
of cancer patients with increased blood polyamine levels
might also be increased. In addition, orally administered
radiolabeled polyamines have been shown to be immedi-
ately distributed to almost all organs and tissues
[29,39,40].
Polyamine concentrations in the blood vary consider-
ably among healthy individuals such that concentrations
are not necessarily higher in cancer patients than in
otherwise normal subjects [41,42] and this wide varia-
tion precludes the use of polyamine levels as a tumor
marker as well as making detection of differences in
polyamine concentrations in normal tissues of cancer
patients and normal subjects difficult. The kinesis of
polyamines may allow distant tissues and organs to
influence polyamine levels of all cells in an organism.
4. Polyamines and cancer spread
Patients with increased polyamine levels either in the
blood or urine are reported to have more advanced dis-
ease and worse prognosis compared to those with low
levels, regardless of the type of malignancy [4-9].
Because polyamines are essential for cell growth, the
increased capability of polyamine synthesis could reflect
enhanced tumor proliferation. Therefore, inhibition of
polyamine synthesis and availability by cancer cells
could retard cancer cell growth. The efficacy of polya-
mine depletion is prominent in animal experiments.
Inhibition of polyamine synthesis by DL-a-difluoro-
methylornithine (DFMO), an inhibitor of ODC that cat-
alyzes the first rate-limiting step in polyamine
biosynthesis, with or without methylglyoxal-bis-guanyl-
hydrazone (MGBG), an inhibitor of S-Adenosylmethio-
nine (SAM) that is required for polyamine synthesis,
successfully suppressed tumor growth and prolonged
survival of tumor-bearing animals [43-46]. Although the
efficacy of polyamine restriction is not as apparent in
humans as in animals [47,48], inhibition of polyamine
synthesis by DFMO successfully suppressed the progres-
sion of neoplastic disease [49-52].
However, a major factor that directly influences the
prognosis of patients with malignant disease is the cap-
ability of cancer cells to invade surrounding tissues and
organs and evade immune cell defenses to metastasize
to distant organs. In animal experiments, inhibition of
polyamine synthesis by DFMO and/or MGBG not only
reduced tumor growth but also decreased the amount of
metastasis, resulting in prolonged survival of tumor
bearing animals [43,44,46,53-55]. Therefore, the effect of
polyamines on the metastatic potential of cancer cells,
the host’s anti-tumor immunity, and the corresponding
mechanisms involved should be taken into
consideration.
5. Mechanism of metastasis and involvement of
polyamines (Figure 2)
There are several steps that occur during metastasis:
separation of cancer cells from the tumor cluster (5-a);
transmigration of cells from the original cluster to the
circulation (5-b); and rooting and colonization in new
organs and tissues (5-c) [56,57]. In addition, metastasis
is completed only when cancer cells can successfully
escape from the anti-tumor immune function of the
host during this process (5-d). In this section, the
mechanism of cancer metastasis and the involvement of
polyamines are discussed.
5-a. Separation of cancer cells from the tumor cluster,
and the role of polyamines
Cancer metastasis begins when cancer cells separate
from the tumor cluster. This separation is initiated by
decreased cell adhesion, which is normally maintained
by the presence of adhesion molecules involved in inter-
cellular binding and binding between cells and the
extracellular matrix. Hypoxia, a common condition in
cancer tissues, exerts a strong pressure on cells to sepa-
rate from the tumor cluster and migrate into circulation
[58,59]. Despite their de novo angiogenesis, solid tumors
have scattered regions where oxygen delivery is compro-
mised due to diffusion limitations, structural abnormal-
ities of tumor microvessels, and disturbed
microcirculation [60]. The cellular response to hypoxia
involves the stabilization and resultant increase in levels
of hypoxia inducible factor-1 (HIF-1), a transcription
factor that enhances gene expression to promote
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invasion [61]. Among these, suppression of adhesion
molecules induced by hypoxia-induced HIF-1 stabiliza-
tion is a strong selective pressure that enhances out-
growth of cells with high-grade malignancy. CD44 and
E-cadherin are adhesion molecules whose expression
decreases in response to hypoxia [62,63].
In cells exposed to chronic hypoxia, polyamine synth-
esis is decreased, while the ability to take up polyamines
from the surroundings is increased [64,65]. Cells in a
hypoxic environment have a resultant decrease in de
novo polyamine synthesis and a concurrent increased
capacity to take up polyamines from surrounding tis-
sues, e.g. from cancer cells under normoxic conditions
that are capable of producing abundant polyamines. We
reported that cancer cells under hypoxia lose regulation
of polyamine homeostasis and have increased polyamine
uptake from surrounding tissues (Figure 2B, 1) [66]. The
expression of the adhesion molecule CD44 is suppressed
in response to hypoxia. Reduced CD44 expression is
reported to promote cancer metastasis and invasion,
allowing detachment of cancer cells from the primary
tumor cluster and seems to contribute to the increased
migration capacity of hypoxic HT-29 cells [67,68]. In
conjunction with hypoxia, increases in extracellular
spermine specifically augmented hypoxia-induced
decreases in CD44 expression, and these decreases cor-
related well with increased migration of cancer cells
(HT-29) in a dose-dependent manner [66]. In addition,
several experiments indicated a possible role for polya-
mines in the invasive potential of cancer cells [53,55,69].
5-b. Role of polyamines in cancer cell transmigration to
the circulation
Cancer invasion is the process in which cancer cells
migrate through surrounding tissues and enter into a
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Hypoxia-induced migration from cancer cluster
and vessel entry
2
1 Polyamine transfer from normoxic cancer cells to hypoxic cancer cells
Transfer to surrounding cells
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Figure 2 Mechanism of cancer metastasis. A.C a n c e rc e l l sp r o d u c ep r o t e a s e st od e s t r o yt h esurrounding matrix, and produce proteins to
create new vessels. In cancer tissues, there are areas where the oxygen supply is poor, which induces hypoxia. Hypoxic cancer cells lose their
adhesion characteristics and have enhanced capacity for migration. B. (1) Polyamines synthesized by cancer cells are transferred to cancer cells
under hypoxic conditions that have increased capacity for polyamine uptake and decreased intracellular polyamine synthesis. The increase in
polyamine concentration due to increased polyamine uptake decreases adhesion of cancer cells by decreasing adhesion molecule expression. (2)
Polyamines are transferred to the blood cells. Increased polyamine uptake by immune cells results in decreased production of tumoricidal
cytokines and the amount of adhesion molecules, and these eventually attenuate the cytotoxic activities of immune cells.
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ported throughout the body and establish secondary
tumors. Blood vessel entry requires that cancer cells not
only have increased motility but also secrete enzymes
that degrade the surrounding cells’ extracellular matrix
(ECM), which is composed of the interstitial matrix and
basement membrane, and provides structural support to
cells. Cancer cells produce various proteinases, such as
serine proteinase, matrix metalloproteinases (MMPs),
cathepsins, and plasminogen activator that degrade the
ECM [70-72]. In addition, cancer cells have the ability
to create new blood vessels in t h et u m o r ,i . e .a n g i o g e n -
esis, so that cancer cells can obtain supplies of blood
and oxygen [73].
Increased polyamine synthesis appears to be accompa-
nied by cancer invasiveness as ODC overexpression
enhances the invasive characteristics of cancer cells [74].
In contrast, inhibition of polyamine synthesis by the
ODC inhibitor DFMO attenuates the invasive character-
istics of cancer cells [53,55,75], and supplementation
with polyamine reverses the DFMO-induced decrease in
invasive qualities [75]. The close correlation between
increased polyamine synthesis and increased MMP
synthesis has also been shown using DFMO, which
caused decreases in cancer cell expression and concen-
trations of MMPs, such as matrilysin, meprin, and
MMP-7 [76,77].
As mentioned above, increased polyamine synthesis is
also accompanied by angiogenesis that is stimulated by
cellular production of several factors, including vascular
endothelial growth factor, which allow tumor tissues to
grow and survive by obtaining sufficient blood supplies
[78]. DFMO has been shown to exert its anti-tumor
activity by inhibiting the proliferation of endothelial
cells [79].
5-c. Possible role of polyamines on cell rooting and
colonization at secondary tumor sites
Cancer cells that invade blood vessels and escape from
immune system detection in circulation anchor to
endothelial vasculature to establish new sites of growth.
Upon vessel entry, cancer cells have access to abundant
oxygen supplies that could enable cancer cells to restore
their original activities such as increased gene expression
that translates to enhanced enzymatic activities for poly-
amine synthesis, proteinase, and angiogenesis factors.
Considering the results of our study, the expression of
CD44 of normoxic cancer cells is higher than that of
hypoxic cells [66], suggesting that the circulating cancer
cells possibly recover their original adhesion characteris-
tics. Once cancer cells anchor to the vessel wall of tis-
sues and organs at secondary growth sites, they invade
and rapidly grow because of their increased capacity to
synthesize polyamines indispensable for cell growth and
proteins that degrade the tissue matrix and create new
vessels.
5-d. Polyamines help cancer cells escape immune system
detection
Immune suppression, often observed in cancer patients,
accelerates cancer spread. Various defects in cellular
functions indicative of immune suppression have been
reported, including attenuated adhesion properties of
peripheral blood mononuclear cells (PBMCs) [80-82],
impaired production of tumoricidal cytokines and che-
mokines [83-85], and decreased cytotoxic activity of
killer cells, especially lymphokine activated killer (LAK)
cells [86-89]. Several investigators have suggested that
circulating factors that inhibit host immune activities
are present in cancer patients [89-91]. The suppression
of immune function in cancer patients can be restored
following tumor eradication, further suggesting the pre-
sence of increased immunosuppressive substance(s) in
cancer patients [83,84,89,91].
The increases in blood polyamine concentrations in
cancer patients reflect increased polyamine concentra-
tions in blood cells, mainly in red and white blood cells
(Figure 2B, 2). The in vitro effects of polyamines on
immune functions were first reported over 30 years ago
[92]. However, later analysis revealed that the reported
immunosuppressive effects are induced not by the direct
effect of polyamines but by substances produced by the
interaction between polyamines and serum amine oxi-
dase, present exclusively in ruminants, making these
results difficult to extend to humans, which lack this
enzyme. Nonetheless, animal experiments have shown
that polyamine deprivation prevents the development of
tumor-induced immunosuppression [93].
The adhesion characteristics of immune cells are
important for eliciting anti-tumor cytotoxic activity,
because adhesion is crucial for immune cell recognition
of tumor cells [94]. Due to decreased adhesion, immune
cells fail to recognize cancer cells or exert tumoricidal
activities. Such decreases in immune cell adhesion are
observed not only in cancer patients but also in patients
having non-cancerous lesions [82]. These findings sug-
gest the possibility that common factor(s), not specifi-
cally produced in cancer patients, can induce
immunosuppressive conditions. Polyamines are one
such factor, because blood polyamine levels, namely
levels in blood cells including immune cells, are often
increased in patients with various diseases [36,95-97].
Immune cells also take up polyamines form their sur-
roundings [98,99], and the increase in blood polyamine
concentrations often observed in cancer patients as well
as in patients with other diseases reflects the increased
polyamine levels in leukocytes [36,100]. We have shown
that increased concentrations of spermine or spermidine
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sacrificing cell viability and activity.
The time- and dose-dependent decrease in adhesion
produced by polyamines was accompanied by decreases
in the expression of lymphocyte function-associated
antigen-1 (LFA-1), which consists of an integrin alpha L
(CD11a) and beta 2 (CD18) chain [41]. Polyamines in
particular decrease the number of cells expressing bright
CD11a. Such suppression was exclusively observed for
LFA-1 with most other adhesion molecules tested unaf-
fected by polyamines. The suppression of LFA-1 expres-
sion by polyamines was further confirmed in human
healthy volunteers with polyamines suppressing LFA-1
expression on PBMCs, regardless of the volunteer’sa g e
[41]. In addition to LFA-1 suppression by polyamines,
the number of CD56 bright cells was decreased by poly-
amines in vitro, although the effect was not confirmed
in vivo. LFA-1 and CD56 contribute to the induction of
tumoricidal cell activities, especially lymphokine acti-
vated killer (LAK) activity [101,102]. LAK cells, which
have tumoricidal activities against established (existing)
tumors, are induced by co-culture with IL-2 [103,104].
In animal experiments, polyamine deprivation reversed
the tumor inoculation-induced suppression of IL-2 pro-
duction without decreasing the number of T lympho-
cytes [93]. In addition, polyamines (spermine and
spermidine) inhibit the production of tumoricidal cyto-
kines, such as tumor necrosis factor (TNF), and chemo-
kines in vitro, while they do not inhibit production of
transforming growth factor beta, which has immunosup-
pressive properties [105-107]. Conversely, in animal
experiments, polyamine deprivation has been shown to
enhance chemokine production, reverse tumor inocula-
tion-induced inhibition of killer cell activity, and prevent
tumor-induced immune suppression [108,109].
TNF is able to induce apoptotic cell death and to
attack and destroy cancer cells [110], while LFA-1 and
CD56, especially bright CD11a and bright CD56 cells,
are required for the induction of LAK cell cytotoxic
activity [111,112]. Polyamines suppress LAK cytotoxicity
without decreasing cell viability and activity in vitro, and
the changes in blood spermine levels are negatively
associated with changes in LAK cytotoxicity in cancer
patients [42].
6. Sources of polyamines other than cancer cells
Food is an important source of polyamines. Polyamines
in the intestinal lumen are absorbed quickly and distrib-
uted to all organs and tissues [29,39,40]. Moreover, con-
tinuous intake of polyamine-rich food gradually
increases blood polyamine levels [30,31]. Therefore, the
restricted intake of food polyamine and inhibition of
polyamine synthesis by microbiota in the intestine with
or without inhibitor-induced inhibition of polyamine
synthesis is reported to have favorable effects on cancer
therapy [33,113-115].
Trauma, such as surgery, is itself considered to
increase the risk of cancer spread through various
mechanisms [116-118]. Blood concentration and urinary
excretion of polyamines are known to increase after sur-
gery, although the origin of this increase is not well
established [97,119]. Our previous study showed that
increases in blood polyamine levels are inversely asso-
ciated with anti-tumor LAK cytotoxicities in patients
who have undergone surgery [42]. In addition to
mechanisms previously postulated for post-traumatic
cancer spread, post-operative increases in polyamines
may be another factor that accelerates tumor growth.
Conclusion
As polyamines are essential for cell growth, one of the
mechanisms by which polyamines accelerate tumor
growth is through the increased availability of this indis-
pensable growth factor. In addition, polyamines seem to
accelerate tumor invasion and metastasis not only by
suppressing immune system activity against established
(already existing) tumors but also by enhancing the abil-
ity of invasive and metastatic capability of cancer cells.
When considering the mechanism by which polyamines
elicit their biological activities on immune and cancer
cell functions, inhibition of polyamine uptake by cells
seems to be an important target for polyamine-based
cancer therapy particularly because inhibition of polya-
mine synthesis alone failed to produce a favorable effect
on cancer treatments in several clinical trials. In addi-
tion to inhibiting polyamine synthesis and supply, inhi-
bition of polyamine uptake via the polyamine
transporter may have beneficial effects [120,121].
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